394 related articles for article (PubMed ID: 19190803)
1. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
2. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
3. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
[TBL] [Abstract][Full Text] [Related]
4. Atypical hemolytic uremic syndrome due to factor H autoantibody.
Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
[TBL] [Abstract][Full Text] [Related]
5. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.
Józsi M; Licht C; Strobel S; Zipfel SL; Richter H; Heinen S; Zipfel PF; Skerka C
Blood; 2008 Feb; 111(3):1512-4. PubMed ID: 18006700
[TBL] [Abstract][Full Text] [Related]
6. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
8. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
Dragon-Durey MA; Blanc C; Marliot F; Loirat C; Blouin J; Sautes-Fridman C; Fridman WH; Frémeaux-Bacchi V
J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
[TBL] [Abstract][Full Text] [Related]
9. The role of defective complement control in hemolytic uremic syndrome.
Zipfel PF; Misselwitz J; Licht C; Skerka C
Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
[TBL] [Abstract][Full Text] [Related]
10. Atypical haemolytic uraemic syndrome.
Kavanagh D; Goodship TH; Richards A
Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
[TBL] [Abstract][Full Text] [Related]
11. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome.
Zipfel PF; Mache C; Müller D; Licht C; Wigger M; Skerka C;
Pediatr Nephrol; 2010 Oct; 25(10):2009-19. PubMed ID: 20157737
[TBL] [Abstract][Full Text] [Related]
12. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
13. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS).
Westra D; Volokhina E; van der Heijden E; Vos A; Huigen M; Jansen J; van Kaauwen E; van der Velden T; van de Kar N; van den Heuvel L
Nephrol Dial Transplant; 2010 Jul; 25(7):2195-202. PubMed ID: 20106822
[TBL] [Abstract][Full Text] [Related]
14. Haemolytic uraemic syndrome.
Kavanagh D; Goodship T
Nephron Clin Pract; 2011; 118(1):c37-42. PubMed ID: 21071971
[TBL] [Abstract][Full Text] [Related]
15. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
[TBL] [Abstract][Full Text] [Related]
16. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
[TBL] [Abstract][Full Text] [Related]
17. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
Strobel S; Hoyer PF; Mache CJ; Sulyok E; Liu WS; Richter H; Oppermann M; Zipfel PF; Józsi M
Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
[TBL] [Abstract][Full Text] [Related]
18. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.
Fremeaux-Bacchi V; Kemp EJ; Goodship JA; Dragon-Durey MA; Strain L; Loirat C; Deng HW; Goodship TH
J Med Genet; 2005 Nov; 42(11):852-6. PubMed ID: 15784724
[TBL] [Abstract][Full Text] [Related]
19. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
[TBL] [Abstract][Full Text] [Related]
20. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
Hofer J; Janecke AR; Zimmerhackl LB; Riedl M; Rosales A; Giner T; Cortina G; Haindl CJ; Petzelberger B; Pawlik M; Jeller V; Vester U; Gadner B; van Husen M; Moritz ML; Würzner R; Jungraithmayr T;
Clin J Am Soc Nephrol; 2013 Mar; 8(3):407-15. PubMed ID: 23243267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
